Literature DB >> 11586093

Elevated COX-2 expression in cervical carcinoma: reduced cause-specific survival and pelvic control.

D K Gaffney1, J Holden, K Zempolich, K J Murphy, A P Dicker, M Dodson.   

Abstract

The purpose of this study was to correlate the level of cyclooxygenase-2 (COX-2) expression in carcinoma of the cervix with the clinical endpoints: local control, cause-specific survival, and patterns of failure in patients treated with radiotherapy. Formalin-fixed, paraffin-embedded tumor biopsies were stained for COX-2. Clinical factors such as stage, grade, tumor size, pre- and posttreatment hemoglobin level, and radiotherapy dose were also evaluated. Actuarial local control rates and cause-specific survival were determined according to the Kaplan-Meier method. COX-2 distribution staining was the only prognostic factor that was associated with local control and cause-specific survival. High COX-2 distribution staining was associated with decreased local control and decreased cause-specific survival by log rank comparison of Kaplan-Meier survival curves. The 5-year cause-specific survival rates for tumors with low versus high COX-2 distribution values were 90% and 22%, respectively (p = 0.0003). Actuarial pelvic control at 5 years was superior in patients with low COX-2 distribution staining (92%) compared with high staining (42%, p = 0.005). COX-2 staining intensity was found to correlate positively with tumor size (p = 0.02). These findings indicate that increased expression of COX-2 yields reduced pelvic control and cause-specific survival in patients with invasive carcinoma of the cervix treated with radiotherapy. Previously, inhibition of COX-2 has been demonstrated to sensitize tumors to radiation without effect on normal tissue. Taken together, these data may support a novel therapeutic application of COX-2 inhibitors in the treatment of carcinoma of the cervix.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11586093     DOI: 10.1097/00000421-200110000-00006

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  5 in total

1.  Loss of the EP2 prostaglandin E2 receptor in immortalized human keratinocytes results in increased invasiveness and decreased paxillin expression.

Authors:  Raymond L Konger; Glynis A Scott; Yvonne Landt; Jack H Ladenson; Alice P Pentland
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

2.  The effect of HIV and HPV coinfection on cervical COX-2 expression and systemic prostaglandin E2 levels.

Authors:  Daniel W Fitzgerald; Karl Bezak; Oksana Ocheretina; Cynthia Riviere; Thomas C Wright; Ginger L Milne; Xi Kathy Zhou; Baoheng Du; Kotha Subbaramaiah; Erin Byrt; Matthew L Goodwin; Arash Rafii; Andrew J Dannenberg
Journal:  Cancer Prev Res (Phila)       Date:  2011-12-01

3.  Cyclooxygenase-2 expression in human irradiated uveal melanomas.

Authors:  Pinar C Ozdal; Sonia Callejo; Amanda L Caissie; Chaim Edelstein; Silvin Bakalian; Raul N G Vianna; Miguel N Burnier
Journal:  Int Ophthalmol       Date:  2007-06-30       Impact factor: 2.031

4.  Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartments in cervical cancer: clinical implications.

Authors:  G Ferrandina; L Lauriola; G F Zannoni; M G Distefano; F Legge; V Salutari; M Gessi; N Maggiano; G Scambia; F O Ranelletti
Journal:  Br J Cancer       Date:  2002-11-04       Impact factor: 7.640

5.  The effect of cyclooxygenase-2 expression on tumor volume response in patients treated with radiotherapy for uterine cervical cancer.

Authors:  Min Kyu Kang; Won Park; Yoon-La Choi; Eun Yoon Cho; Geunghwan Ahn; Heerim Nam; Seung Jae Huh; Yong Chan Ahn; Do Hoon Lim; Dong Ryul Oh; Duk Soo Bae; Byoung Gie Kim
Journal:  J Korean Med Sci       Date:  2009-11-09       Impact factor: 2.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.